产品详情
仅用于工业应用或科学研究,不可用于人类或动物的临床诊断或治疗,非药用. Bemarituzumab is a first-in-class, humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has the potential for cancer research